Impact of COVID-19 Vaccines on Cerebrovascular Health
Recruiting
Observational Study
Stroke
Stroke, Acute
Stroke, Ischemic
Dementia
Brain Ischemia
Alzheimer Disease
Brain Diseases
Major Adverse Cardiovascular Event
Arterial Thromboembolism
Venous Thromboembolism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Chinese University of Hong Kong · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.
On the ot…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.
Exclusion Criteria:
1. Citizens with clinically evident stroke or dementia prior to recruitment; or
2. Citizens who are unable to provide an informed consent; or
3. Cit…
Contacts